Immune Cell Engagers ICEs Market Size, Share and Growth Analysis 2026 to 2035

Report Id: 3397 Pages: 180 Last Updated: 14 January 2026 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Market Segmentation:

Immune Cell Engagers (ICEs) Market by Product Type -

  •  Bispecific Antibodies
    •  T-cell Engagers (BiTEs, DARTs)
    •  NK-cell Engagers
    •  Myeloid Engagers
  •  Trispecific/Multispecific Antibodies
  •  Engineered Cell Therapies
    •  TAC-T cells
    •  CAR-NK with engager payloads

Immune Cell Engagers (ICEs) Market seg

Immune Cell Engagers (ICEs) Market by Target Antigen-

  •  Oncology Targets
    •  Hematologic
    •  Solid Tumors
  •  Autoimmune/Inflammatory Targets
    •  B-cell Depletion
    •  Cytokine Modulation
    •  Immune Checkpoints

Immune Cell Engagers (ICEs) Market by Mechanism of Action -

  •  Immune Cell Recruitment
    •  T-cell
    •  NK-cell
    •  Macrophage
  •  Signal Modulation
    •  Co-stimulation
    •  Cytokine armoring
  •  Conditional Activation
    •  Protease-cleavable masks
    •  Tumor microenvironment sensors

Immune Cell Engagers (ICEs) Market by Therapeutic Area-

  •  Oncology
    •  Hematologic Malignancies:
      •  B-cell ALL, NHL (DLBCL, FL)
      •  Multiple myeloma (BCMA-targeted)
    •  Solid Tumors:
      •  Breast (HER2)
      •  Prostate (PSMA)
      •  Lung (EGFR)
  •  Autoimmune/Inflammatory
    •  Rheumatoid Arthritis
    •  Lupus
    •  IBD

Immune Cell Engagers (ICEs) Market by Development Stage -

  •  Clinical Phase
  •  Marketed/Approved

By Region-

North America-

  •  The US
  •  Canada

Europe-

  •  Germany
  •  The UK
  •  France
  •  Italy
  •  Spain
  •  Rest of Europe

Asia-Pacific-

  •  China
  •  Japan
  •  India
  •  South Korea
  •  South East Asia
  •  Rest of Asia Pacific

Latin America-

  •  Brazil
  •  Argentina
  •  Mexico
  •  Rest of Latin America

Middle East & Africa-

  •  GCC Countries
  •  South Africa
  •  Rest of Middle East and Africa

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Immune Cell Engagers (ICEs) Market Snapshot

Chapter 4. Global Immune Cell Engagers (ICEs) Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Porter's Five Forces Analysis

4.7. Incremental Opportunity Analysis (US$ MN), 2025-2035

4.8. Global Immune Cell Engagers (ICEs) Market Penetration & Growth Prospect Mapping (US$ Mn), 2026-2035

4.9. Competitive Landscape & Market Share Analysis, By Key Player (2026)

4.10. Use/impact of AI on IMMUNE CELL ENGAGERS (ICES) Industry Trends

Chapter 5. Immune Cell Engagers (ICEs) Market Segmentation 1: By Product Type, Estimates & Trend Analysis

5.1. Market Share By Product Type, 2025 & 2035

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Product Type:

5.2.1. Bispecific Antibodies

5.2.1.1. T-cell Engagers (BiTEs, DARTs)

5.2.1.2. NK-cell Engagers

5.2.1.3. Myeloid Engagers

5.2.2. Trispecific/Multispecific Antibodies

5.2.3. Engineered Cell Therapies

5.2.3.1. TAC-T cells

5.2.3.2. CAR-NK with engager payloads

Chapter 6. Immune Cell Engagers (ICEs) Market Segmentation 2: By Target Antigen, Estimates & Trend Analysis

6.1. Market Share By Target Antigen, 2025 & 2035

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Target Antigen:

6.2.1. Oncology Targets

6.2.1.1. Hematologic

6.2.1.2. Solid Tumors

6.2.2. 2.2 Autoimmune/Inflammatory Targets

6.2.2.1. B-cell Depletion

6.2.2.2. Cytokine Modulation

6.2.2.3. Immune Checkpoints

Chapter 7. Immune Cell Engagers (ICEs) Market Segmentation 3: By Mechanism of Action, Estimates & Trend Analysis

7.1. Market Share By Mechanism of Action, 2025 & 2035

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Mechanism of Action:

7.2.1. Immune Cell Recruitment

7.2.1.1. T-cell

7.2.1.2. NK-cell

7.2.1.3. Macrophage

7.2.2. Signal Modulation

7.2.2.1. Co-stimulation

7.2.2.2. Cytokine armoring

7.2.3. Conditional Activation

7.2.3.1. Protease-cleavable masks

7.2.3.2. Tumor microenvironment sensors

Chapter 8. Immune Cell Engagers (ICEs) Market Segmentation 4: By Therapeutic Area, Estimates & Trend Analysis

8.1. Market Share By Therapeutic Area, 2025 & 2035

8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Therapeutic Area:

8.2.1. Oncology

8.2.1.1. Hematologic Malignancies:

8.2.1.1.1. B-cell ALL, NHL (DLBCL, FL)

8.2.1.1.2. Multiple myeloma (BCMA-targeted)

8.2.1.2. Solid Tumors:

8.2.1.2.1. Breast (HER2)

8.2.1.2.2. Prostate (PSMA)

8.2.1.2.3. Lung (EGFR)

8.2.2. Autoimmune/Inflammatory

8.2.2.1. Rheumatoid Arthritis

8.2.2.2. Lupus

8.2.2.3. IBD

Chapter 9. Immune Cell Engagers (ICEs) Market Segmentation 5: By Development Stage, Estimates & Trend Analysis

9.1. Market Share By Development Stage, 2025 & 2035

9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Development Stage:

9.2.1. Clinical Phase

9.2.2. Marketed/Approved

Chapter 10. Immune Cell Engagers (ICEs) Market Segmentation 5: Regional Estimates & Trend Analysis

10.1. Global Immune Cell Engagers (ICEs) Market, Regional Snapshot 2025 & 2035

10.2. North America

10.2.1. North America Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035

10.2.1.1. US

10.2.1.2. Canada

10.2.2. North America Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Product Type, 2022-2035

10.2.3. North America Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Mechanism of Action, 2022-2035

10.2.4. North America Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Target Antigen, 2022-2035

10.2.5. North America Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Therapeutic Area, 2022-2035

10.2.6. North America Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Development Stage, 2022-2035

10.3. Europe

10.3.1. Europe Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035

10.3.1.1. Germany

10.3.1.2. U.K.

10.3.1.3. France

10.3.1.4. Italy

10.3.1.5. Spain

10.3.1.6. Rest of Europe

10.3.2. Europe Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Product Type, 2022-2035

10.3.3. Europe Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Mechanism of Action, 2022-2035

10.3.4. Europe Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Target Antigen, 2022-2035

10.3.5. Europe Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Therapeutic Area, 2022-2035

10.3.6. Europe Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Development Stage, 2022-2035

10.4. Asia Pacific

10.4.1. Asia Pacific Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035

10.4.1.1. India

10.4.1.2. China

10.4.1.3. Japan

10.4.1.4. Australia

10.4.1.5. South Korea

10.4.1.6. Hong Kong

10.4.1.7. Southeast Asia

10.4.1.8. Rest of Asia Pacific

10.4.2. Asia Pacific Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Product Type, 2022-2035

10.4.3. Asia Pacific Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Mechanism of Action, 2022-2035

10.4.4. Asia Pacific Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Target Antigen, 2022-2035

10.4.5. Asia Pacific Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Therapeutic Area, 2022-2035

10.4.6. Asia Pacific Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Development Stage, 2022-2035

10.5. Latin America

10.5.1. Latin America Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035

10.5.1.1. Brazil

10.5.1.2. Mexico

10.5.1.3. Rest of Latin America

10.5.2. Latin America Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Product Type, 2022-2035

10.5.3. Latin America Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Mechanism of Action, 2022-2035

10.5.4. Latin America Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Target Antigen, 2022-2035

10.5.5. Latin America Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Therapeutic Area, 2022-2035

10.5.6. Latin America Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Development Stage, 2022-2035

10.6. Middle East & Africa

10.6.1. Middle East & Africa Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts by country, 2022-2035

10.6.1.1. GCC Countries

10.6.1.2. Israel

10.6.1.3. South Africa

10.6.1.4. Rest of Middle East and Africa

10.6.2. Middle East & Africa Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Product Type, 2022-2035

10.6.3. Middle East & Africa Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Mechanism of Action, 2022-2035

10.6.4. Middle East & Africa Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Target Antigen, 2022-2035

10.6.5. Middle East & Africa Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Therapeutic Area, 2022-2035

10.6.6. Middle East & Africa Immune Cell Engagers (ICEs) Market Revenue (US$ Million) Estimates and Forecasts By Development Stage, 2022-2035

Chapter 11. Competitive Landscape

11.1. Major Mergers and Acquisitions/Strategic Alliances

11.2. Company Profiles

11.2.1. Amgen (Blinatumomab)

11.2.1.1. Business Overview

11.2.1.2. Key Product/Service

11.2.1.3. Financial Performance

11.2.1.4. Geographical Presence

11.2.1.5. Recent Developments with Business Strategy

11.2.2. Johnson & Johnson/Genmab (Teclistamab)

11.2.3. Regeneron (Odronextamab)

11.2.4. Pfizer (Elranatamab)

11.2.5. Sanofi (SAR446309)

11.2.6. Affimed (AFM13)

11.2.7. Innate Pharma (IPH6101)

11.2.8. Dragonfly Therapeutics (DF1001)

11.2.9. GT Biopharma (GTB-3550)

11.2.10. Immunocore (Tebentafusp)

11.2.11. Merus (MCLA-158)

11.2.12. Xencor (Plamotamab)

11.2.13. Harpoon Therapeutics (HPN328)

11.2.14. Gilead/Tizona (TTX-080)

11.2.15. Jounce Therapeutics (JTX-8064)

11.2.16. UCB Pharma (CD19×CD3)

11.2.17. Horizon Therapeutics/Amgen (B-cell depleters)

11.2.18. Viela Bio (CD40L×CD3)

11.2.19. MorphoSys (CD19×CD3)

11.2.20. CytomX (Probody TCE)

11.2.21. Xilio Therapeutics (Tumor-activated)

11.2.22. Numab Therapeutics (NM21-1480)

11.2.23. Immatics (IMA401)

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
8081
Security Code field cannot be blank!

Frequently Asked Questions

Immune Cell Engagers (ICEs) Market is expected to grow with at a 26.4% CAGR during the forecast period for 2026 to 2035.

Amgen (Blinatumomab), Johnson & Johnson/Genmab (Teclistamab), Regeneron (Odronextamab), Pfizer (Elranatamab), Sanofi (SAR446309), Affimed (AFM13), Innate Pharma (IPH6101), Dragonfly Therapeutics (DF1001), GT Biopharma (GTB-3550), Immunocore (Tebentafusp), Merus (MCLA-158), Xencor (Plamotamab), Harpoon Therapeutics (HPN328), Gilead/Tizona (TTX-080), Jounce Therapeutics (JTX-8064), UCB Pharma (CD19×CD3), Horizon Therapeutics/Amgen (B-cell depleters), Viela Bio (CD40L×CD3), MorphoSys (CD19×CD3), CytomX (Probody TCE), Xilio Therapeutics (Tumor-activated), Numab Therapeutics (NM21-1480), Immatics (IMA401)

Product Type, Target Antigen, Mechanism of Action, Therapeutic Area, Development Stage are the key segments of the Immune Cell Engagers (ICEs) Market.

North America region is leading the Immune Cell Engagers (ICEs) Market.

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying